Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 10, 2014, Pages 2746-2758

  Férir, Geoffrey ^a   Huskens, Dana ^a,c   Noppen, Sam ^a   Koharudin, Leonardus M I ^b   Gronenborn, Angela M ^b   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Synapse BV   (Netherlands)

Author keywords

Anti HIV activity; Broad spectrum; Glycosylation; Microbicide; OAA; OAAH (OPA); PBMCs

Indexed keywords

AGGLUTININ; ANTIVIRUS AGENT; CARBOHYDRATE; CARBOHYDRATE BINDING PROTEIN; CD209 ANTIGEN; GLYCOPROTEIN GP 120; GRIFFITHSIN; HIPPEASTRUM HYBRID AGGLUTININ; LECTIN; MANNOSE 9; MICROBICIDE; MONOCLONAL ANTIBODY 2G12; OSCILLATORIA AGARDHII HYBRID AGGLUTININ; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BACTERIAL PROTEIN; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN BINDING;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING KINETICS; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN IIIB); HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN NL4.3); HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; LYMPHOMA CELL LINE; MITOGENESIS; NONHUMAN; OSCILLATORIA; OSCILLATORIA AGARDHII; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN FAMILY; SURFACE PLASMON RESONANCE; SYNCYTIUM; VIRION; VIRUS INACTIVATION; VIRUS REPLICATION; VIRUS TRANSMISSION; ANTIVIRAL RESISTANCE; CELL LINE; DRUG EFFECTS; GIANT CELL; IC50; KINETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MONONUCLEAR CELL; VIROLOGY;

AGGLUTININS; ANTI-HIV AGENTS; BACTERIAL PROTEINS; CELL LINE; DRUG RESISTANCE, VIRAL; GIANT CELLS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LECTINS; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; OSCILLATORIA; PROTEIN BINDING;

EID: 84919748011     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku220     Document Type: Article

References (57)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74.
2. Tilton JC, Doms RW. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 2010; 85: 91-100.
3. Kwong PD, Wyatt R, Robinson J et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-59.
4. Leonard CK, SpellmanMW, Riddle L et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990; 265: 10373-82.
5. Wyatt R, Kwong PD, Desjardins E et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393: 705-11.
6. Huskens D, Schols D. Algal lectins as potential HIV microbicide candidates. Mar Drugs 2012; 10: 1476-97.
7. Alexandre KB, Gray ES, Lambson BE et al. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins griffithsin, cyanovirin-N and scytovirin. Virology 2010; 402: 187-96.
8. Balzarini J, Van Laethem K, Peumans WJ et al. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 2006; 80: 8411-21.
9. Bewley CA, Cai M, Ray S et al. New carbohydrate specificity and HIV-1 fusion blocking activity of the cyanobacterial protein MVL: NMR, ITC and sedimentation equilibrium studies. J Mol Biol 2004; 339: 901-14.
10. Bokesch HR, O'Keefe BR, McKee TC et al. A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry 2003; 42: 2578-84.
11. Boyd MR, Gustafson KR, McMahon JB et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997; 41: 1521-30.
12. Emau P, Tian B, O'Keefe BR et al. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol 2007; 36: 244-53.
13. Férir G, Palmer KE, Schols D. Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. Virology 2011; 417: 253-8.
14. Férir G, Palmer KE, Schols D. Griffithsin, alone and combined with all classes of antiretroviral drugs, potently inhibits HIV cell-cell transmission and destruction of CD4+ T cells. J Antivir Antiretrovir 2012; 4: 103-12.
15. Huskens D, Férir G, Vermeire K et al. Microvirin, a novel a(1,2)-mannosespecific lectin isolated from Microcystis aeruginosa, has comparable anti-HIV-1 activity as cyanovirin-N, but a much higher safety profile. J Biol Chem 2010; 285: 24845-54.
16. Kouokam JC, Huskens D, Schols D et al. Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. PLoS One 2011; 6: e22635.
17. Xiong S, Fan J, Kitazato K. The antiviral protein cyanovirin-N: the current state of its production and applications. Appl Microbiol Biotechnol 2010; 86: 805-12.
18. Mori T, O'Keefe BR, Sowder RC II et al. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 2005; 280: 9345-53.
19. Sato Y, Murakami M, Miyazawa K et al. Purification and characterization of a novel lectin from a freshwater cyanobacterium, Oscillatoria agardhii. Comp Biochem Physiol B Biochem Mol Biol 2000; 125: 169-77.
20. Sato Y, Okuyama S, Hori K. Primary structure and carbohydrate binding specificity of a potent anti-HIV lectin isolated from the filamentous cyanobacterium Oscillatoria agardhii. J Biol Chem 2007; 282: 11021-9.
21. Koharudin LM, Gronenborn AM. Structural basis of the anti-HIV activity of the cyanobacterial Oscillatoria agardhii agglutinin. Structure 2011; 19: 1170-81.
22. Sato T, Hori K. Cloning, expression, and characterization of a novel anti-HIV lectin from cultured cyanobacterium, Oscillatoria agardhii. Fisher Sci 2009; 75: 743-53.
23. Koharudin LM, Kollipara S, Aiken C et al. Structural insights into the anti-HIV activity of the Oscillatoria agardhii agglutinin homolog lectin family. J Biol Chem 2012; 287: 33796-811.
24. Koharudin LM, Furey W, Gronenborn AM. Novel fold and carbohydrate specificity of the potent anti-HIV cyanobacterial lectin from Oscillatoria agardhii. J Biol Chem 2011; 286: 1588-97.
25. Kehr JC, Zilliges Y, Springer A et al. A mannan binding lectin is involved in cell-cell attachment in a toxic strain of Microcystis aeruginosa. Mol Microbiol 2006; 59: 893-906.
26. Pauwels R, Andries K, Desmyter J et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990; 343: 470-4.
27. Huskens D, Van Laethem K, Vermeire K et al. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology 2007; 360: 294-304.
28. Hoorelbeke B, Huskens D, Férir G et al. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob Agents Chemother 2010; 54: 3287-301.
29. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drug or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
30. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-81.
31. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008; 8: 447-57.
32. Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 2008; 6: 815-26.
33. Geijtenbeek TB, Kwon DS, Torensma R et al. DC-SIGN, a dendritic cellspecific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100: 587-97.
34. Huang X, JinW, Griffin GE et al. Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin. J Gen Virol 2011; 92: 2367-73.
35. Huskens D, Vermeire K, Vandemeulebroucke E et al. Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int J Biochem Cell Biol 2008; 40: 2802-14.
36. O'Keefe BR, Vojdani F, Buffa V et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci USA 2009; 106: 6099-104.
37. Férir G, Vermeire K, Huskens D et al. Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs). Antiviral Res 2011; 90: 200-4.
38. Bewley CA, Gustafson KR, Boyd MR et al. Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat Struct Biol 1998; 5: 571-8.
39. Lagenaur LA, Sanders-Beer BE, Brichacek B et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol 2011; 4: 648-57.
40. Tsai CC, Emau P, Jiang Y et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2003; 19: 535-41.
41. Tsai CC, Emau P, Jiang Y et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmissionmodels. AIDS Res Hum Retroviruses 2004; 20: 11-8.
42. Sigal A, Kim JT, Balazs AB et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477: 95-8.
43. Del Portillo A, Tripodi J, Najfeld V et al. Multiploid inheritance of HIV-1 during cell-to-cell infection. J Virol 2011; 85: 7169-76.
44. Agosto LM, Zhong P, Munro J et al. Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission. PLoS Pathog 2014; 10: e1003982.
45. Hladik F, Doncel GF. Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res 2010; 88 Suppl 1: S3-9.
46. Barrientos LG, Matei E, Lasala F et al. Dissecting carbohydratecyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition. Protein Eng Des Sel 2006; 19: 525-35.
47. Bewley CA. Solution structure of a cyanovirin-N:Mana1-2Mana complex: structural basis for high-affinity carbohydrate-mediated binding to gp120. Structure 2001; 9: 931-40.
48. Botos I, O'Keefe BR, Shenoy SR et al. Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides. J Biol Chem 2002; 277: 34336-42.
49. Calarese DA, Scanlan CN, Zwick MB et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003; 300: 2065-71.
50. Shahzad-ul-Hussan S, Gustchina E, Ghirlando R et al. Solution structure of the monovalent lectin microvirin in complex with Man(a)(1-2)Man provides a basis for anti-HIV activity with low toxicity. J Biol Chem 2011; 286: 20788-96.
51. Van Damme EJ, Goldstein IJ, Peumans WJ. A comparative study of mannose-binding lectins from the Amaryllidaceae. Phytochemistry 1991; 30: 509-14.
52. VanDamme EJ, PeumansWJ, Pusztai A et al. Handbook of Plant Lectins: Properties and Biomedical Applications. Chichester: John Wiley & Sons, 1998.
53. Balzarini J, Van Laethem K, Hatse S et al. Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: a new therapeutic concept to hit the Achilles heel of HIV. J Biol Chem 2005; 280: 41005-14.
54. Férir G, Huskens D, Palmer KE et al. Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV type 1, HIV type 2, and selected carbohydrate-binding agent-resistant HIV type 1 strains. AIDS Res Hum Retroviruses 2012; 28: 1513-23.
55. Arrighi JF, Pion M, Garcia E et al. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J Exp Med 2004; 200: 1279-88.
56. Chalmet K, Dauwe K, Foquet L et al. Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission. J Infect Dis 2012; 205: 174-84.
57. Gianella S, Mehta SR, Young JA et al. Sexual transmission of predicted CXCR4-tropic HIV-1 likely originating from the source partner's seminal cells. Virology 2012; 434: 2-4.